Regenxbio announces phase II aaviate ® The interim data of the trial were positive. Abbv-rgx-314 administered through sclera was used to treat wet AMD.

Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.

Initial findings from a Phase 1b trial examining treatments with Quemliclustat suggest encouraging survival rates for patients with previously untreated advanced pancreatic cancer.

Vertex Discloses Clearance by the US FDA for CASGEVY™ (exagamglogene autotemcel) as a Therapeutic Option for Beta Thalassemia Patients Requiring Regular Blood Transfusions.

GALDERMA 2024: Phase III trials of RelabotulinumtoxinA show favorable outcomes and extended effectiveness in addressing both glabellar lines and lateral canthal lines at once.

Aviceda Therapeutics Reveals Preliminary Results from Initial Segment of Phase 2/3 SIGLEC Study on AVD-104, Indicating Encouraging Safety Profile and Initial Efficacy Signals in Individuals with Geographic Atrophy.

In molecular and microbiology, a vector refers to a method or agent that transports genetic material into a cell or organism.

Aruna Bio has received FDA approval for its investigational new drug (IND) application, allowing AB126, its pioneering exosome therapy.

In biology, a variant refers to a specific region of the genome that differs between two genomes, or an individual organism with characteristics that deviate from the standard within a species.

Sarepta Therapeutics Launches Participant Selection for Phase 3 Trial, EMERGENE, Investigating SRP-9003 in Limb-Girdle Muscular Dystrophy 2E/R4 Treatment.

Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.